Skip to content
Research Article Open access CC BY 4.0

Snake Venom Components as Therapeutic Leads: A Critical Narrative Review of Established Medicines and Translational Barriers

Uzuazokaro Mark-Maria Agatemor

International Journal of Biochemistry Research & Review · pp. 100–107 · Published 3 Nov 2026

10.9734/ijbcrr/2026/v35i61183

Abstract

Background: Snake venoms contain biologically active molecules that interact with enzymes, adhesion receptors and ion channels. These interactions have informed drug development, although toxicity and poor translation constrain many proposed applications. Objective: To critically examine the therapeutic relevance of snake venom components, distinguish demonstrated clinical utility from experimental activity, and identify requirements for further development. Approach: Targeted web searches of PubMed-indexed records and original publisher pages were conducted on 13 September 2026. Foundational discovery studies, randomised trials and selected mechanistic investigations were prioritised. Public prescribing information was consulted for established medicines. Evidence was organised by mechanism and experimental setting without meta-analysis or formal certainty grading. Findings: Bradykinin-potentiating peptides and disintegrins informed the development of captopril, eptifibatide and tirofiban. Their translation depended on molecular redesign and clinical evaluation rather than administration of crude venom. Defibrinogenating and fibrinolytic candidates illustrate less successful pathways: ancrod produced inconsistent stroke outcomes, and alfimeprase did not improve the principal clinical endpoint in placebo-controlled peripheral arterial occlusion studies. Textilinin-1, anticancer disintegrins, antimicrobial enzymes and mambalgins provide mechanistic leads. However, normal-cell toxicity, problematic cancer models and differences between rodent and human ion-channel pharmacology limit extrapolation. Conclusion: Snake venom is a productive source of pharmacological templates. Future progress requires defined molecular products, human-relevant target validation, exposure-linked safety assessment and clinically meaningful comparators. Claims of therapeutic benefit should reflect the level of evidence for each individual molecule.

Snake venom drug discovery disintegrins haemostasis phospholipase A2 L-amino acid oxidase mambalgins translational pharmacology

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.